LAWRENCE, Mass.–(BUSINESS WIRE)–[RUBIX LS], a minority-led life science analysis agency specializing in options to assist minorities inside scientific trials, introduced right this moment that it has formally launched its therapeutics division. Whereas the trade stays challenged on supporting scientific analysis inclusion reeling from the devastating results of the COVID-19 pandemic, Rubix is positioning its lead scientific trial platform to catalyze improvements for designing and growing therapeutics that may goal situations exhibited by minority and under-represented affected person populations.
“We’ve got invested in new amenities and scientific analysis capability inside the neurodegenerative and infectious illness well being disciplines. These investments will permit Rubix LS to develop it’s rising product pipeline for decisive and inclusive well being outcomes in numerous illness states within the coming months.” – Reginald Swift Ph.D, Founder & CEO of Rubix LS
About RUBIX LS
Rubix LS, based in 2016, is a culturally-centric life science analysis agency that’s constructing information, merchandise, processes, and applications to wholly assist the scientific analysis continuum that features minority information units in each section of the life science growth ecosystem. Enabling its the usage of digital scientific trials, it’s bridging the scientific and operational experience to design customized made options that improve minority affected person consideration, recruitment, engagement, assist, and schooling in order that the life science trade could make higher merchandise for everybody. For extra details about Rubix LS go to its web site at www.rubixls.com